Formycon CFO Enno Spillner interviewed by Andreas Schmidt from the SdK

In a video interview with Andreas Schmidt from Schutzgemeinschaft der Kapitalanleger e.V. (SdK), Enno Spillner explains why Formycon can waive the phase III trial for the pembrolizumab biosimilar candidate FYB206. He also addresses the current dynamics on the US biosimilar market, which have led to reduced sales expectations for the ustekinumab biosimilar FYB202 and the temporary pause in the commercialization of the ranibizumab biosimilar FYB201 in the U.S.

The interview is held in German.